What is Clinilabs?
Clinilabs Drug Development Corporation operates as the sole global, full-service CRO dedicated exclusively to CNS drug development. With over two decades of experience, the company has facilitated more than 700 CNS clinical trials, contributing to the approval of 19 new therapies across 10 indications. Clinilabs partners with pharmaceutical and biotechnology firms, offering comprehensive clinical development services from first-in-human studies through Phase 3 trials. Their expertise is crucial in accelerating the market entry of novel CNS medicines, addressing a critical need in patient care for a range of debilitating conditions.
How much funding has Clinilabs raised?
Clinilabs has raised a total of $4M across 2 funding rounds:
Debt
$2M
Debt
$2M
Debt (2020): $2M with participation from PPP
Debt (2021): $2M led by PPP
What's next for Clinilabs?
The substantial enterprise-level funding positions Clinilabs for accelerated growth and expanded service offerings within the highly specialized CNS drug development sector. This strategic investment is expected to bolster their capabilities in managing complex clinical trials, potentially enabling the company to take on larger-scale projects and further solidify its market leadership. Future developments may include enhanced technological integration for trial management, expansion of global operational reach, and deeper collaborations with biopharmaceutical innovators aiming to address unmet needs in neurological and psychiatric treatments.
See full Clinilabs company page
